Scarica l'app Stockscreener
1.61
0.62%
-0.01
Dopo l'orario di chiusura:
1.61
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GANX Giù?
Forum
Previsione
Precedente Chiudi:
$1.62
Aprire:
$1.62
Volume 24 ore:
192.99K
Relative Volume:
0.66
Capitalizzazione di mercato:
$48.21M
Reddito:
$210.70K
Utile/perdita netta:
$-21.37M
Rapporto P/E:
-1.4636
EPS:
-1.1
Flusso di cassa netto:
$-21.10M
1 W Prestazione:
-9.04%
1M Prestazione:
-5.85%
6M Prestazione:
-29.39%
1 anno Prestazione:
+26.77%
Intervallo 1D:
$1.59
$1.66
Intervallo di 1 settimana:
$1.5251
$1.9349
Portata 52W:
$0.89
$3.19
Gain Therapeutics Inc Stock (GANX) Company Profile
Nome
Gain Therapeutics Inc
Settore
Industria
Telefono
(301) 500-1556
Indirizzo
4800 HAMPDEN LANE, BETHESDA
Confronta GANX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GANX
Gain Therapeutics Inc
|
1.61 | 53.00M | 210.70K | -21.37M | -21.10M | -1.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Gain Therapeutics Inc Stock (GANX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2024-12-06 | Iniziato | ROTH MKM | Buy |
| 2024-08-14 | Ripresa | Oppenheimer | Outperform |
| 2021-04-12 | Iniziato | BTIG Research | Buy |
| 2021-04-12 | Iniziato | Oppenheimer | Outperform |
Gain Therapeutics Inc Borsa (GANX) Ultime notizie
What analysts say about Gain Therapeutics Inc. stock outlookFree Best Stocks to Buy Today - Newser
Gain Therapeutics Announces $7 Million Public Offering - TipRanks
Form 424B5 Gain Therapeutics, Inc. - StreetInsider
Why Gain Therapeutics Inc. stock attracts strong analyst attentionDaily Stock Radar - beatles.ru
Gain Therapeutics Announces Pricing of $7.0 Million Public Offering - The Manila Times
Gain Therapeutics Secures $7M Funding to Advance Novel Parkinson's Treatment Pipeline - Stock Titan
US Futures Trade Mixed As June Inflation Ticks Up: ASML, Morgan Stanley, Goldman Sachs, BofA Earnings In Focus - Benzinga
Why Data Storage Shares Are Trading Higher By 35%; Here Are 20 Stocks Moving Premarket - Benzinga
Gain Therapeutics' High-Stakes Gamble: Can GT-02287 Rewrite the Neurodegenerative Treatment Playbook? - AInvest
Gain Therapeutics Plans Public Offering of Common Shares, Warrants - MarketScreener
Gain Therapeutics falls on equity offering plans - TradingView
Gain Therapeutics Announces Proposed Public Offering - The Manila Times
Gain Therapeutics stock falls after announcing public offering By Investing.com - Investing.com Canada
Gain Therapeutics stock falls after announcing public offering - Investing.com
Gain Therapeutics, Inc. Proposes Underwritten Public Offering of Common Stock and Warrants - Quiver Quantitative
Gain Therapeutics Unveils Strategic Public Offering: Funding Next-Gen Parkinson's Treatment Development - Stock Titan
Why Alaunos Therapeutics Inc. stock attracts strong analyst attentionRapid Gain Targets - Newser
How Atossa Therapeutics Inc. stock performs during market volatilityDaily Gain Forecast - Newser
How Maze Therapeutics Inc. stock performs during market volatilityDaily Gain Forecast - Newser
What makes Gain Therapeutics Inc. stock price move sharplyReturn Optimized Trade Insights - Newser
What makes Akero Therapeutics Inc. stock price move sharplyFree Access to Community - Newser
Why Sangamo Therapeutics Inc. stock attracts strong analyst attentionDaily Gain Forecast - Newser
What makes Tango Therapeutics Inc. stock price move sharplyDaily Gain Forecast - Newser
What makes Spero Therapeutics Inc. stock price move sharplyDaily Gain Forecast - Newser
How Gain Therapeutics Inc. stock performs during market volatilityMomentum Swing Watchlist - Newser
What makes Lexeo Therapeutics Inc. stock price move sharplyDaily Gain Forecast - Newser
Why Cabot Corporation stock attracts strong analyst attentionFree Step-by-Step Investment Guide - Newser
How Enliven Therapeutics Inc. stock performs during market volatilityDaily Gain Forecast - Newser
Gain Therapeutics, Inc. (NASDAQ:GANX) Receives $8.20 Consensus Target Price from Brokerages - Defense World
Anti-GPC3 Therapies Market Gains Traction with Key Players Advancing Pipeline for Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Gastric Cancer, and Others | DelveInsight - The Malaysian Reserve
Beam Therapeutics (BEAM) Surges 5.7%: Is This an Indication of Further Gains? - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: RxSight (RXST), Gain Therapeutics (GANX) and Edwards Lifesciences (EW) - The Globe and Mail
Parkinson's Disease Pipeline Appears Robust With 130+ Key Pharma Companies Actively Working In The Therapeutics Segment Delveinsight - Menafn.com
Institutional investors are Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) biggest bettors and were rewarded after last week's US$47m market cap gain - Yahoo Finance
HC Wainwright Reaffirms Buy Rating for Gain Therapeutics (NASDAQ:GANX) - Defense World
Gain Therapeutics stock advances as Phase 1b trial enrollment exceeds expectations - Investing.com India
Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson’s Disease With or Without a GBA1 Mutation - TradingView
Viking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to Note - MSN
Gain Therapeutics Doubles Authorized Common Stock Shares - TipRanks
Gene-Editing Stocks Gain on LLY-VERV Deal Announcement - TradingView
SpringWorks Therapeutics (SWTX) Continues Strong Yearly Run, Showing Over 29% YTD Gain - Daily Chhattisgarh News
Aquestive stock gains on FDA review for allergy drug (AQST) - Seeking Alpha
Stellantis (NYSE:STLA) Receives Consensus Rating of “Hold” from Analysts - Defense World
Gain Therapeutics, Inc. (NASDAQ:GANX) Given Consensus Rating of “Buy” by Analysts - Defense World
Pharmaceutical Stocks Worth Watching – June 13th - Defense World
CRISPR Therapeutics Gains 14% in a Month: How to Play the Stock? - Yahoo Finance
Gain Therapeutics to Participate in Upcoming Investor Conferences - Bluefield Daily Telegraph
Gain Therapeutics Opens Access to Management: CEO Featured at Two Major Biotech Investor Conferences - Stock Titan
Aquestive Therapeutics: Anaphylm Could Gain Significant Market Share (NASDAQ:AQST) - Seeking Alpha
Telix Pharmaceuticals (ASX:TLX) Gains Portugal Approval for Illuccix in Prostate Cancer Detection - Yahoo Finance
Viking Therapeutics, Inc. (VKTX) Outpaces Stock Market Gains: What You Should Know - sharewise
Gain Therapeutics Inc Azioni (GANX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.64%
0.37%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):